Articles

Sort by
Previous Page Page 2 of 18 Next Page
  1. Research

    A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1–42 peptide in human plasma with utility for studies of Alzheimer’s disease therapeutics

    Amyloid-β 1–42 peptide (Aβ1–42) is associated with plaque formation in the brain of patients with Alzheimer’s disease (AD). Pharmacodynamic studies of AD therapeutics that lower the concentrations of Aβ1–42 in pe...

    Linan Song, D. Richard Lachno, David Hanlon, Adam Shepro, Andreas Jeromin, Dipika Gemani, Jayne A. Talbot, Margaret M. Racke, Jeffrey L. Dage and Robert A. Dean

    Alzheimer's Research & Therapy 2016 8:58

    Published on: 15 December 2016

  2. Research

    LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1ΔE9 transgenic mice

    Accumulating evidence implicates the neuroendocrine immunomodulation (NIM) network in the physiopathological mechanism of Alzheimer’s disease (AD). Notably, we previously revealed that the NIM network is dysre...

    Jian-Hui Wang, Xi Lei, Xiao-Rui Cheng, Xiao-Rui Zhang, Gang Liu, Jun-Ping Cheng, Yi-Ran Xu, Ju Zeng, Wen-Xia Zhou and Yong-Xiang Zhang

    Alzheimer's Research & Therapy 2016 8:57

    Published on: 13 December 2016

  3. Research

    Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease

    According to new diagnostic guidelines for Alzheimer’s disease (AD), biomarkers enable estimation of the individual likelihood of underlying AD pathophysiology and the associated risk of progression to AD deme...

    Panagiotis Alexopoulos, Lukas Werle, Jennifer Roesler, Nathalie Thierjung, Lena Sophie Gleixner, Igor Yakushev, Nikolaos Laskaris, Stefan Wagenpfeil, Philippos Gourzis, Alexander Kurz and Robert Perneczky

    Alzheimer's Research & Therapy 2016 8:51

    Published on: 9 December 2016

  4. Research

    Brain activation in frontotemporal and Alzheimer’s dementia: a functional near-infrared spectroscopy study

    Frontotemporal dementia is an increasingly studied disease, the underlying functional impairments on a neurobiological level of which have not been fully understood. Patients with the behavioral-subtype fronto...

    Florian G. Metzger, Betti Schopp, Florian B. Haeussinger, Katja Dehnen, Matthis Synofzik, Andreas J. Fallgatter and Ann-Christine Ehlis

    Alzheimer's Research & Therapy 2016 8:56

    Published on: 8 December 2016

  5. Review

    An update on semantic dementia: genetics, imaging, and pathology

    Progressive and relatively circumscribed loss of semantic knowledge, referred to as semantic dementia (SD) which falls under the broader umbrella of frontotemporal dementia, was officially identified as a clin...

    Ramon Landin-Romero, Rachel Tan, John R. Hodges and Fiona Kumfor

    Alzheimer's Research & Therapy 2016 8:52

    Published on: 5 December 2016

  6. Research

    Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology

    Hyperactivity of the classical axis of the renin-angiotensin system (RAS), mediated by angiotensin II (Ang II) activation of the angiotensin II type 1 receptor (AT1R), is implicated in the pathogenesis of Alzh...

    Patrick Gavin Kehoe, Steffenny Wong, Noura AL Mulhim, Laura Elyse Palmer and J. Scott Miners

    Alzheimer's Research & Therapy 2016 8:50

    Published on: 25 November 2016

  7. Research

    Outcomes measures in a decade of dementia and mild cognitive impairment trials

    In a research study, to give a comprehensive evaluation of the impact of interventions, the outcome measures should reflect the lived experience of the condition. In dementia studies, this necessitates the use...

    Jennifer Kirsty Harrison, Anna H. Noel-Storr, Nele Demeyere, Emma L. Reynish and Terry J. Quinn

    Alzheimer's Research & Therapy 2016 8:48

    Published on: 21 November 2016

  8. Research

    The societal costs of dementia in Sweden 2012 – relevance and methodological challenges in valuing informal care

    In this study, we sought to estimate the societal cost of illness in dementia in Sweden in 2012 using different costing approaches to highlight methodological issues.

    Anders Wimo, Linus Jönsson, Laura Fratiglioni, Per Olof Sandman, Anders Gustavsson, Anders Sköldunger and Lennarth Johansson

    Alzheimer's Research & Therapy 2016 8:59

    Published on: 18 November 2016

    The Erratum to this article has been published in Alzheimer's Research & Therapy 2017 9:12

  9. Research

    Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study

    A large, prospective, 2-year, randomized study in patients with mild-to-moderate Alzheimer’s disease or mixed dementia demonstrated reductions in mortality and cognitive/functional decline in galantamine-treat...

    Klaus Hager, Alan S. Baseman, Jeffrey S. Nye, H. Robert Brashear, John Han, Mary Sano, Bonnie Davis and Henry M. Richards

    Alzheimer's Research & Therapy 2016 8:47

    Published on: 15 November 2016

  10. Research

    Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review

    Current Alzheimer’s disease (AD) research initiatives focus on cognitively healthy individuals with biomarkers that are associated with the development of AD. It is unclear whether biomarker results should be ...

    S. A. S. A. Bemelmans, K. Tromp, E. M. Bunnik, R. J. Milne, S. Badger, C. Brayne, M. H. Schermer and E. Richard

    Alzheimer's Research & Therapy 2016 8:46

    Published on: 10 November 2016

  11. Research

    Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients

    There is a need to investigate biomarkers that are indicative of the progression of dementia in ethnic patient populations. The disparity of information in these populations has been the focus of many clinical...

    Rinko Grewal, Mona Haghighi, Shuai Huang, Amanda G. Smith, Chuanhai Cao, Xiaoyang Lin, Daniel C. Lee, Nancy Teten, Angela M. Hill and Maj-Linda B. Selenica

    Alzheimer's Research & Therapy 2016 8:43

    Published on: 18 October 2016

  12. Research

    ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension

    Results from a phase 2a study indicated that treatment with the novel α7 nicotinic acetylcholine receptor agonist ABT-126 25 mg once daily (QD) was associated with a trend for improvement in cognition in subje...

    Laura M. Gault, Robert A. Lenz, Craig W. Ritchie, Andreas Meier, Ahmed A. Othman, Qi Tang, Scott Berry, Yili Pritchett and Weining Z. Robieson

    Alzheimer's Research & Therapy 2016 8:44

    Published on: 18 October 2016

  13. Research

    Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs

    Mild parkinsonian signs (MPS) are common in older people and are associated with an increased risk of different neurodegenerative diseases. This study prospectively evaluates the longitudinal course of cogniti...

    Stefanie Lerche, Kathrin Brockmann, Andrea Pilotto, Isabel Wurster, Ulrike Sünkel, Markus A. Hobert, Anna-Katharina von Thaler, Claudia Schulte, Erik Stoops, Hugo Vanderstichele, Victor Herbst, Britta Brix, Gerhard W. Eschweiler, Florian G. Metzger, Walter Maetzler and Daniela Berg

    Alzheimer's Research & Therapy 2016 8:42

    Published on: 10 October 2016

  14. Research

    The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease

    Synaptic degeneration is a central pathogenic event in Alzheimer’s disease that occurs early during the course of disease and correlates with cognitive symptoms. The pre-synaptic vesicle protein synaptotagmin-...

    Annika Öhrfelt, Ann Brinkmalm, Julien Dumurgier, Gunnar Brinkmalm, Oskar Hansson, Henrik Zetterberg, Elodie Bouaziz-Amar, Jacques Hugon, Claire Paquet and Kaj Blennow

    Alzheimer's Research & Therapy 2016 8:41

    Published on: 3 October 2016

  15. Research

    Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease

    The recent development of tau-specific positron emission tomography (PET) tracers has allowed in vivo quantification of regional tau deposition and offers the opportunity to monitor the progression of tau path...

    Laure Saint-Aubert, Ove Almkvist, Konstantinos Chiotis, Rita Almeida, Anders Wall and Agneta Nordberg

    Alzheimer's Research & Therapy 2016 8:38

    Published on: 29 September 2016

  16. Review

    Drug development in Alzheimer’s disease: the path to 2025

    The global impact of Alzheimer’s disease (AD) continues to increase, and focused efforts are needed to address this immense public health challenge. National leaders have set a goal to prevent or effectively t...

    Jeffrey Cummings, Paul S. Aisen, Bruno DuBois, Lutz Frölich, Clifford R. Jack, Roy W. Jones, John C. Morris, Joel Raskin, Sherie A. Dowsett and Philip Scheltens

    Alzheimer's Research & Therapy 2016 8:39

    Published on: 20 September 2016

  17. Meeting report

    Alzheimer’s Research UK 2016 Conference report

    The annual Alzheimer’s Research UK (ARUK) Conference was hosted by the Manchester and North West Network Centre on March 8–9, 2016. In this report, we provide a summary of the research presented.

    Rosa M. Sancho, Carla J. Cox, Laura E. Phipps and Simon H. Ridley

    Alzheimer's Research & Therapy 2016 8:35

    Published on: 15 September 2016

  18. Research

    Protective effect of melatonin on soluble Aβ1–42-induced memory impairment, astrogliosis, and synaptic dysfunction via the Musashi1/Notch1/Hes1 signaling pathway in the rat hippocampus

    Amyloid-beta (Aβ) plays a key role in Alzheimer’s disease (AD) pathogenesis, and soluble Aβ oligomers are more cytotoxic than Aβ fibrils. Recent evidence suggests that Notch signaling is affected by AD and oth...

    Shuman Zhang, Pan Wang, Lili Ren, Chunli Hu and Jing Bi

    Alzheimer's Research & Therapy 2016 8:40

    Published on: 15 September 2016

  19. Research

    Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer’s disease

    Familial Alzheimer’s disease (FAD) is caused by mutations in the amyloid precursor protein (APP) or presenilin (PS). Most PS mutations, which account for the majority of FAD cases, lead to an increased ratio o...

    Jean-François Blain, Matthew G. Bursavich, Emily A. Freeman, Lori A. Hrdlicka, Hilliary E. Hodgdon, Ting Chen, Don E. Costa, Bryce A. Harrison, Sudarshan Kapadnis, Deirdre A. Murphy, Scott Nolan, Zhiming Tu, Cuyue Tang, Duane A. Burnett, Holger Patzke and Gerhard Koenig

    Alzheimer's Research & Therapy 2016 8:34

    Published on: 30 August 2016

  20. Review

    A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline

    Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline...

    Penny A. Dacks, Joshua J. Armstrong, Stephen K. Brannan, Aaron J. Carman, Allan M. Green, M. Sue Kirkman, Lawrence R. Krakoff, Lewis H. Kuller, Lenore J. Launer, Simon Lovestone, Elizabeth Merikle, Peter J. Neumann, Kenneth Rockwood, Diana W. Shineman, Richard G. Stefanacci, Priscilla Velentgas…

    Alzheimer's Research & Therapy 2016 8:33

    Published on: 20 August 2016

Previous Page Page 2 of 18 Next Page

Advertisement